{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T13:27:05Z","timestamp":1783344425492,"version":"3.54.6"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,14]],"date-time":"2022-01-14T00:00:00Z","timestamp":1642118400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Tumor flare reaction (TFR) is a clinical syndrome, which is mainly associated with painful and swollen lymph nodes or splenomegaly, slight fever, bone pain, and skin rash during treatment with immune-related drugs, causing difficulty in distinguishing TFR from disease progression. Brentuximab vedotin (BV) and programmed death 1 (PD-1) inhibitor are two ideal drugs used for the treatment of classic Hodgkin lymphoma, but few studies have reported their adverse effects in association with TFR. The efficacy and safety of monotherapy or combination therapy with these drugs needs to be further evaluated. It is essential to determine whether treated patients can develop TFR, thus enabling more accurate diagnosis and treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>A 26-year-old female patient, diagnosed with classic Hodgkin lymphoma, had received 2 + 3 cycles of ABVD chemotherapy (a combination of adriamycin, bleomycin, vinblastine, and dacarbazine) and 4 cycles of PD-1 inhibitor (tislelizumab) therapy but exhibited poor efficacy. Subsequently, she was given combination therapy of BV (100 mg) + tislelizumab (200 mg). However, a slight fever, painful and swollen axillary lymph nodes, multiple skin rashes with pruritus, joint pain, and fatigue with poor appetite appeared during the treatment. Ultrasound (US) scans revealed that multiple lymph nodes were significantly enlarged. After treatment with low-dose dexamethasone and cetirizine, the symptoms were alleviated. A biopsy of the left axillary lymph node revealed that lymphoid tissue exhibited proliferative changes, without tumor cell infiltration. These findings were consistent with the clinical and pathological manifestations of TFR.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Combination therapy with BV and PD-1 inhibitor was effective in the treatment of relapsed or refractory classic Hodgkin lymphoma. The results suggest that the combination therapy may cause TFR, and biopsy and also continuous imaging observation are important to determine the disease stage. This approach allows clinicians to decide whether to continue the current treatment plan, and alerts them to the occurrence of excessive activation of the immune system.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2021.756583","type":"journal-article","created":{"date-parts":[[2022,1,14]],"date-time":"2022-01-14T04:53:20Z","timestamp":1642136000000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Tumor Flare Reaction in a Classic Hodgkin Lymphoma Patient Treated With Brentuximab Vedotin and Tislelizumab: A Case Report"],"prefix":"10.3389","volume":"12","author":[{"given":"Chunting","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijia","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingsong","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donghua","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study","volume":"30","author":"Pro","year":"2012","journal-title":"J Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-2069","article-title":"Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate","volume":"16","author":"Okeley","year":"2010","journal-title":"Clin Cancer Res"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab Vedotin With Chemotherapy for Stage III or IV Hodgkin\u2019s Lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-10-811224","article-title":"Interim Results of Brentuximab Vedotin in Combination With Nivolumab in Patients With Relapsed or Refractory Hodgkin Lymphoma","volume":"131","author":"Herrera","year":"2018","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003127","article-title":"Brentuximab Vedotin With Chemotherapy for Stage III\/IV Classical Hodgkin Lymphoma: 3-Year Update of the ECHELON-1 Study","volume":"135","author":"Straus","year":"2020","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000334","article-title":"Novel Biomarker Approaches in Classic Hodgkin Lymphoma","volume":"24","author":"Aoki","year":"2018","journal-title":"Cancer J"},{"key":"B7","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13045-018-0601-9","article-title":"Advances in CD30- and PD-1-Targeted Therapies for Classical Hodgkin Lymphoma","volume":"11","author":"Wang","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.3390\/cancers11081071","article-title":"Immunotherapy in Hodgkin Lymphoma: Present Status and Future Strategies","volume":"11","author":"Vassilakopoulos","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B9","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1177\/1043454220966590","article-title":"Commonly Reported Adverse Events Associated With Pediatric Immunotherapy: A Systematic Review From the Children\u2019s Oncology Group","volume":"38","author":"Withycombe","year":"2021","journal-title":"J\u00a0Pediatr Oncol Nurs"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-019-00768-6","article-title":"A Phase 2, Open-Label Study of Brentuximab Vedotin in Patients With CD30-Expressing Solid Tumors","volume":"37","author":"Sharman","year":"2019","journal-title":"Invest New Drugs"},{"key":"B11","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/bjh.17073","article-title":"Results of a UK National Cancer Research Institute Phase II Study of Brentuximab Vedotin Using a Response-Adapted Design in the First-Line Treatment of Patients With Classical Hodgkin Lymphoma Unsuitable for Chemotherapy Due to Age, Frailty or Comorbidity (BREVITY)","volume":"193","author":"Gibb","year":"2020","journal-title":"Br J Haematol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60165-9","article-title":"Brentuximab Vedotin as Consolidation Therapy After Autologous Stem-Cell Transplantation in Patients With Hodgkin\u2019s Lymphoma at Risk of Relapse or Progression (AETHERA): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial","volume":"385","author":"Moskowitz","year":"2015","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.12.008","article-title":"Safety and Efficacy of Anti-Programmed Death 1 Antibodies in Patients With Cancer and Pre-Existing Autoimmune or Inflammatory Disease","volume":"91","author":"Danlos","year":"2018","journal-title":"Eur J Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.0393","article-title":"Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-Analysis","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01286-z","article-title":"Tislelizumab: First Approval","volume":"80","author":"Lee","year":"2020","journal-title":"Drugs"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0545-2","article-title":"Treatment of Relapsed or Refractory Classical Hodgkin Lymphoma With the Anti-PD-1, Tislelizumab: Results of a Phase 2, Single-Arm, Multicenter Study","volume":"34","author":"Song","year":"2020","journal-title":"Leukemia"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s40336-018-0294-7","article-title":"Hodgkin Lymphoma and Imaging in the Era of Anti-PD-1\/PD-L1 Therapy","volume":"6","author":"Kirienko","year":"2018","journal-title":"Clin Transl Imaging"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1148\/rg.2017170085","article-title":"Immune Checkpoint Inhibitor Cancer Therapy: Spectrum of Imaging Findings","volume":"37","author":"Wang","year":"2017","journal-title":"Radiographics"},{"key":"B19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1182\/blood-2019-123801","article-title":"Brentuximab Vedotin (BV) and Lenalidomide (Len) in Relapsed and Refractory (R\/R) Cutaneous (CTCL) and Peripheral (PTCL) T-Cell Lymphomas; A Planned Interim Analysis of Phase II Trial","volume":"134","author":"William","year":"2019","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.8133","article-title":"Single-Agent Lenalidomide in the Treatment of Previously Untreated Chronic Lymphocytic Leukemia","volume":"29","author":"Chen","year":"2011","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08376.x","article-title":"Lenalidomide-Induced Tumour Flare Reaction in Mantle Cell Lymphoma","volume":"151","author":"Eve","year":"2010","journal-title":"Br J Haematol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/ajh.21571","article-title":"Tumor Flare Reactions and Response to Lenalidomide in Patients With Refractory Classic Hodgkin Lymphoma","volume":"85","author":"Corazzelli","year":"2010","journal-title":"Am J Hematol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0253-2727.2016.09.001","article-title":"The Consensus of the Diagnosis and Treatment of Lymphoplasmacytic Lymphoma\/Walderstrom Macroglobulinemia in China (2016 Version)","volume":"37","year":"2016","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1802917","article-title":"Phase 3 Trial of Ibrutinib Plus Rituximab in Waldenstrom\u2019s Macroglobulinemia","volume":"378","author":"Dimopoulos","year":"2018","journal-title":"N Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25748","article-title":"Tumor Flare Reaction Associated With Lenalidomide Treatment in Patients With Chronic Lymphocytic Leukemia Predicts Clinical Response","volume":"117","author":"Chanan-Khan","year":"2011","journal-title":"Cancer"},{"key":"B26","doi-asserted-by":"publisher","first-page":"932010","DOI":"10.1155\/2013\/932010","article-title":"Lenalidomide and Chronic Lymphocytic Leukemia","volume":"2013","author":"Gonzalez-Rodriguez","year":"2013","journal-title":"BioMed Res Int"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.1008-5734.2019.04.022","article-title":"Lenalidomide-Induced Flammable Tumor Reaction","author":"Chunhui","year":"2019","journal-title":"Adverse Drug React J"},{"key":"B28","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3390\/jpm11030217","article-title":"Early Evaluation of Immunotherapy Response in Lymphoma Patients by 18F-FDG PET\/CT: A Literature Overview","volume":"11","author":"Ferrari","year":"2021","journal-title":"J Pers Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08882.x","article-title":"Biological Effects and Clinical Significance of Lenalidomide-Induced Tumour Flare Reaction in Patients With Chronic Lymphocytic Leukaemia: In Vivo Evidence of Immune Activation and Antitumour Response","volume":"155","author":"Chanan-Khan","year":"2011","journal-title":"Br J Haematol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.5045\/br.2014.49.4.279","article-title":"Tumor Flare Reaction in a Patient With Mantle Cell Lymphoma","volume":"49","author":"Kayar","year":"2014","journal-title":"Blood Res"},{"key":"B31","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3960\/jslrt.20045","article-title":"Transient Atelectasis Due to Hilar Lymph Node Swelling Affected by Lenalidomide-Induced Tumor Flare Reaction","volume":"61","author":"Suyama","year":"2021","journal-title":"J Clin Exp Hematop"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000001083","article-title":"False-Positive 18f-FDG PET\/CT Imaging: Dramatic \u201cFlare Response\u201d After Rituximab Administration","volume":"41","author":"Skoura","year":"2016","journal-title":"Clin Nucl Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.676170","article-title":"Progressive Multifocal Leukoencephalopathy in a Patient With Hodgkin Lymphoma Treated With Brentuximab Vedotin","volume":"53","author":"Wagner-Johnston","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-561878","article-title":"Pancreatitis in Patients Treated With Brentuximab Vedotin: A Previously Unrecognized Serious Adverse Event","volume":"123","author":"Gandhi","year":"2014","journal-title":"Blood"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.756583\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,14]],"date-time":"2022-01-14T04:53:24Z","timestamp":1642136004000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.756583\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,14]]},"references-count":34,"alternative-id":["10.3389\/fimmu.2021.756583"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.756583","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,14]]},"article-number":"756583"}}